Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Perphenazine

FDA-approved product (tablet, oral), marketed as Perphenazine, Trilafon.

Registered studies
34
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Perphenazine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Nausea and vomiting
  • Psychosis
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Phenothiazines with piperazine structure
FDA pharmacologic class
Phenothiazine FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli37.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

34registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Perphenazine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Perphenazine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

    NCT04606264 · start 2023-05-15

    Registered record
    Registry ID
    NCT04606264
    Conditions
    Perioperative Optimization
    Interventions
    Neuraxial Analgesia; Regional Block 1: Paravertebral; Perphenazine; Aprepitant; Dimenhydrinate; Ondansetron 4 MG; Dexamethasone; Regional Block 2: QL1
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-05-15
    Completion
    2025-03-21
    Enrolment
    3,395

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerioperative Optimization
    InterventionNeuraxial Analgesia; Regional Block 1: Paravertebral; Perphenazine; Aprepitant +4 more
    PhasePhase 3
    Registry statusCompleted

  • Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE

    NCT05762146 · start 2022-09-05

    Registered record
    Registry ID
    NCT05762146
    Conditions
    Ischemic Stroke, Acute
    Interventions
    Riociguat; Propylthiouracil; Perphenazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-09-05
    Completion
    2024-04-30
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke, Acute
    InterventionRiociguat; Propylthiouracil; Perphenazine
    PhasePhase 2
    Registry statusUnknown

  • Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers

    NCT04776499 · start 2021-03-18

    Registered record
    Registry ID
    NCT04776499
    Conditions
    Drug Drug Interaction; Safety Issues
    Interventions
    Propylthiouracil, Riociguat, Perphenazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-18
    Completion
    2022-02-28
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Drug Interaction; Safety Issues
    InterventionPropylthiouracil, Riociguat, Perphenazine
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

    NCT04002700 · start 2019-05-06

    Registered record
    Registry ID
    NCT04002700
    Conditions
    Stroke
    Interventions
    Haloperidol; Typical Antipsychotics; Atypical Antipsychotics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-05-06
    Completion
    2019-05-31
    Enrolment
    1,234,412

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke
    InterventionHaloperidol; Typical Antipsychotics; Atypical Antipsychotics
    PhaseNot recorded
    Registry statusCompleted

  • Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)

    NCT03510325 · start 2019-02-12

    Registered record
    Registry ID
    NCT03510325
    Conditions
    Schizophrenia
    Interventions
    Phase 1: Olanzapine; Phase 1: Risperidone; Phase 1: Amisulpride; Phase 1: Aripiprazole; Phase 1: Perphenazine; Phase 2: Olanzapine; Phase 2: Amisulpride; Phase 2: Clozapine; Phase 3A: Clozapine extended treatment or Combined clozapine-MECT therapy; Phase 3B: Clozapine or another SGAs
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-02-12
    Completion
    2023-09-27
    Enrolment
    762

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPhase 1: Olanzapine; Phase 1: Risperidone; Phase 1: Amisulpride; Phase 1: Aripiprazole +6 more
    PhasePhase 3
    Registry statusCompleted

  • Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

    NCT02893371 · start 2016-09

    Registered record
    Registry ID
    NCT02893371
    Conditions
    Bipolar Disorder
    Interventions
    Lithium Carbonate; Lamotrigine; Valproic Acid; Oxcarbazepine; Carbamazepine; Ziprasidone; Risperidone; Quetiapine; Olanzapine; Aripiprazole; Fluoxetine / Olanzapine; Haloperidol; Perphenazine; Clozapine; Asenapine; Lurasidone; Paliperidone; Mirtazapine; Bupropion; Desvenlafaxine; Duloxetine; Venlafaxine; Citalopram; Escitalopram; Fluoxetine; Fluvoxamine; Paroxetine; Sertraline; Vilazodone; Doxepin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2016-09
    Completion
    2019-06-30
    Enrolment
    1,037,352

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionLithium Carbonate; Lamotrigine; Valproic Acid; Oxcarbazepine +26 more
    PhaseNot recorded
    Registry statusTerminated

  • Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT

    NCT02815917 · start 2016-06

    Registered record
    Registry ID
    NCT02815917
    Conditions
    D3 Dopamine Receptor; Cocaine-dependent; Healthy Volunteer
    Interventions
    [18F]FTP PET/CT
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2016-06
    Completion
    2027-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionD3 Dopamine Receptor; Cocaine-dependent; Healthy Volunteer
    Intervention[18F]FTP PET/CT
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

    NCT02600741 · start 2015-07-24

    Registered record
    Registry ID
    NCT02600741
    Conditions
    Schizophrenia
    Interventions
    Caregiver psycho-education and skills training; Caregiver support available at the study site; Paliperidone palmitate; Chlorpromazine; Droperidol; Fluphenazine; Haloperidol; Loxapine; Perphenazine; Pimozide; Prochlorperazine; Thiothixene; Thioridazine; Trifluoperazine; Aripiprazole; Asenapine; Clozapine; Iloperidone; Olanzapine; Paliperidone; Quetiapine; Risperidone; Ziprasidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-07-24
    Completion
    2018-07-05
    Enrolment
    296

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionCaregiver psycho-education and skills training; Caregiver support available at the study site; Paliperidone palmitate; Chlorpromazine +19 more
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

    NCT02431702 · start 2015-07-08

    Registered record
    Registry ID
    NCT02431702
    Conditions
    Schizophrenia; Psychotic Disorders
    Interventions
    Aripiprazole; Haloperidol; Olanzapine; Oral Paliperidone ER; Perphenazine; Quetiapine; Oral Risperidone; Paliperidone Palmitate Injection (PP1M); Paliperidone Palmitate Injection (PP3M)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-07-08
    Completion
    2019-11-12
    Enrolment
    337

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychotic Disorders
    InterventionAripiprazole; Haloperidol; Olanzapine; Oral Paliperidone ER +5 more
    PhasePhase 3
    Registry statusCompleted

  • Antipsychotic Induced Structural and Functional Brain Changes

    NCT02435095 · start 2015-05

    Registered record
    Registry ID
    NCT02435095
    Conditions
    Schizophrenia
    Interventions
    Maintenance treatment; Intermittent treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-05
    Completion
    2020-08
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionMaintenance treatment; Intermittent treatment
    PhasePhase 4
    Registry statusTerminated

  • Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

    NCT02307396 · start 2015-02-01

    Registered record
    Registry ID
    NCT02307396
    Conditions
    Schizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders
    Interventions
    Olanzapine; Amisulpride; Risperidone; Haloperidol; Quetiapine; Perphenazine; Sulpiride; bromperidol; Zuclopenthixol; Thioridazine; Paliperidone; Ziprasidone; Benperidol; Fluspirilene; Pimozide; Perazine; Fluphenazine; Flupentixole; Sertindole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-02-01
    Completion
    2016-06-22
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders
    InterventionOlanzapine; Amisulpride; Risperidone; Haloperidol +15 more
    PhasePhase 4
    Registry statusCompleted

  • Pharmacovigilance in Gerontopsychiatric Patients

    NCT02374567 · start 2015-01

    Registered record
    Registry ID
    NCT02374567
    Conditions
    Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders
    Interventions
    Phenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine; Valproic Acid; Lamotrigine; Topiramate; Gabapentin; Levetiracetam; Pregabalin; Lacosamide; Clonazepam; Biperiden; Levomepromazine; Fluphenazine; Perphenazine; Perazine; Thioridazine; Haloperidol; Melperone; Pipamperone; Bromperidol; Benperidol; Sertindole; Ziprasidone; Flupentixol; Chlorprothixene; Zuclopenthixol; Fluspirilene; Pimozide; Clozapine; Olanzapine; Quetiapine; Sulpiride; Tiapride; Amisulpride; Prothipendyl; Risperidone; Aripiprazole; Paliperidone; Diazepam; Oxazepam; Lorazepam; Bromazepam; Clobazam; Alprazolam; Hydroxyzine; Buspirone; Chloral Hydrate; Flurazepam; Nitrazepam; Triazolam; Lormetazepam; Temazepam; Midazolam; Brotizolam; Zopiclone; Zolpidem; Zaleplon; Melatonin; Clomethiazole; Diphenhydramine; Promethazine; Imipramine; Clomipramine; Opipramol; Trimipramine; Amitriptyline; Nortriptyline; Doxepin; Maprotiline; Amitriptyline oxide; Fluoxetine; Citalopram; Paroxetine; Sertraline; Fluvoxamine; Escitalopram; Tran
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-01
    Completion
    2017-06-28
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Depression; Schizophrenia; Psychosomatic Disorders +1 more
    InterventionPhenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine +75 more
    PhasePhase 3
    Registry statusTerminated

  • YouScript IMPACT Registry

    NCT02191358 · start 2014-10

    Registered record
    Registry ID
    NCT02191358
    Conditions
    Adverse Drug Events; Adverse Drug Reactions; Drug Interaction Potentiation; Drug Metabolism, Poor, CYP2D6-RELATED; Drug Metabolism, Poor, CYP2C19-RELATED; Cytochrome P450 Enzyme Deficiency; Cytochrome P450 CYP2D6 Enzyme Deficiency; Cytochrome P450 CYP2C9 Enzyme Deficiency; Cytochrome P450 CYP2C19 Enzyme Deficiency; Cytochrome P450 CYP3A Enzyme Deficiency; Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant; Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant; Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-10
    Completion
    2015-08
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Drug Events; Adverse Drug Reactions; Drug Interaction Potentiation; Drug Metabolism, Poor, CYP2D6-RELATED +9 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Lurasidone Effects on Tissue Glutamate in Schizophrenia

    NCT02199743 · start 2013-02

    Registered record
    Registry ID
    NCT02199743
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Lurasidone; Haloperidol; Perphenazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-02
    Completion
    2016-06
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionLurasidone; Haloperidol; Perphenazine
    PhasePhase 4
    Registry statusCompleted

  • Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis

    NCT01765829 · start 2012-11

    Registered record
    Registry ID
    NCT01765829
    Conditions
    Psychosis Nos/Other
    Interventions
    Discontinuation antipsychotic treatment; Antipsychotic treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2012-11
    Completion
    2015-11
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychosis Nos/Other
    InterventionDiscontinuation antipsychotic treatment; Antipsychotic treatment
    PhasePhase 3
    Registry statusUnknown